• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

    2/14/23 4:33:58 PM ET
    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ISO alert in real time by email
    SC 13G/A 1 eh230329913_13ga1-iso.htm AMENDMENT NO. 1

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    IsoPlexis Corp.
    (Name of Issuer)
     
    Common Stock, no par value
    (Title of Class of Securities)
     
    465005106
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       

     

    CUSIP No. 465005106 SCHEDULE 13G Page 2 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    North Sound Trading, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     
      5

    SOLE VOTING POWER

     

    1,033,000

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,033,000

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,033,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.6%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

    CUSIP No. 465005106 SCHEDULE 13G Page 3 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    North Sound Ventures, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     
      5

    SOLE VOTING POWER

     

    210,987

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    210,987

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    210,987

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.5%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

    CUSIP No. 465005106 SCHEDULE 13G Page 4 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    North Sound Management, Inc.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    1,243,987

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,243,987

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,243,987

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.1%

     
    12

    TYPE OF REPORTING PERSON

     

    IA, CO

     

     

       

     

    CUSIP No. 465005106 SCHEDULE 13G Page 5 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    Brian Miller

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    3,644,418

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    3,644,418

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,644,418

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.0%

     
    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

       

     

    CUSIP No. 465005106 SCHEDULE 13G Page 6 of 9

     

     

    ITEM 1. (a) Name of Issuer:
         
        IsoPlexis Corp. (the “Issuer”)
         
      (b) Address of Issuer’s Principal Executive Offices:
       

    35 NE Industrial Road

    Branford, CT 06405

       
    ITEM 2. (a) Name of Person Filing:
       

     

    This statement is being filed on behalf of each of the following persons (each, a “Reporting Person” and, collectively, the “Reporting Persons”):

     

    (1)          North Sound Trading, LP

    (2)          North Sound Ventures, LP

    (3)          North Sound Management, Inc.

    (4)          Brian Miller

         
      (b)

    Address of Principal Business Office, or if none, Residence:

     

    The principal business address for each of the Reporting Persons is:

     

    c/o North Sound Management, Inc.

    115 East Putnam Avenue

    Greenwich, CT 06830

         
      (c) Citizenship:
         
        See row 4 of the cover page of each Reporting Person.
         
      (d) Title of Class of Securities:
         
        See cover page.
         
      (e) CUSIP Number:
         
        See cover page.
         
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
         
      Not applicable.
         
    ITEM 4. OWNERSHIP.
       
      (a)

    Amount beneficially owned:

     

    See row 9 of the cover page of each Reporting Person.

     

    As the general partner of North Sound Trading (“NST”) and North Sound Ventures (“NSV”), North Sound Management (“NS Management”) may be deemed to beneficially own the shares held by NST and NSV.  Mr. Miller is the sole owner of NS Management and may be deemed to beneficially own the shares beneficially owned by NS Management.

         
      (b)

    Percent of class:

     

    See row 11 of the cover page of each Reporting Person.

     

    The calculations of beneficial ownership percentage is based on 40,351,574 shares of Common Stock issued and outstanding as of February 6, 2023, as reported in the Issuer’s Definitive Proxy Statement filed with the Securities and Exchange Commission on February 13, 2023.

     

     

       

     

    CUSIP No. 465005106 SCHEDULE 13G Page 7 of 9

     

      (c) Number of shares as to which such person has:
         
        (i)

    Sole power to vote or to direct the vote:

     

    See row 5 of the cover page of each Reporting Person.

           
        (ii)

    Shared power to vote or to direct the vote:

     

    See row 6 of the cover page of each Reporting Person.

           
        (iii)

    Sole power to dispose or to direct the disposition of:

     

    See row 7 of the cover page of each Reporting Person.

           
        (iv)

    Shared power to dispose or to direct the disposition of:

     

    See row 8 of the cover page of each Reporting Person.

     
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.
       
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.
       
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.
       
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.
       
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
       
    ITEM 10. CERTIFICATION.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

       

     

    CUSIP No. 465005106 SCHEDULE 13G Page 8 of 9

     

    Exhibit Index

    Exhibit No.   Description
         
    99.1   Joint Filing Agreement, dated December 23, 2021, among North Sound Trading LP, North Sound Management, Inc., and Brian Miller (previously filed).

     

       

     

     

    CUSIP No. 465005106 SCHEDULE 13G Page 9 of 9

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  February 14, 2023

     

      NORTH SOUND TRADING, LP  
             
      By: North Sound Management, Inc., its  
      general partner  
             
      By: /s/ Brian Miller  
        Name: Brian Miller  
        Title: President  
         
      NORTH SOUND VENTURES, LP  
             
      By: North Sound Management, Inc., its  
      general partner  
             
      By: /s/ Brian Miller  
        Name: Brian Miller  
        Title: President  
             
      NORTH SOUND MANAGEMENT, INC.  
             
      By: /s/ Brian Miller  
        Name: Brian Miller  
        Title: President  
             
             
      /s/ Brian Miller  
      Brian Miller  

     

     

       

     

    Get the next $ISO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISO

    DatePrice TargetRatingAnalyst
    2/15/2022$17.00 → $12.00Overweight
    Morgan Stanley
    1/27/2022$20.00 → $15.00Outperform
    SVB Leerink
    11/19/2021$24.00Outperform
    Evercore ISI Group
    11/11/2021$17.00 → $20.00Outperform
    SVB Leerink
    11/2/2021$17.00Outperform
    SVB Leerink
    11/2/2021Outperform
    Cowen & Co.
    11/2/2021$16.00Overweight
    Morgan Stanley
    More analyst ratings

    $ISO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis Reports Preliminary Full Year 2022 Revenue

      BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

      1/12/23 4:05:00 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $ISO
    Financials

    Live finance-specific insights

    See more
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

      12/21/22 4:15:00 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

      BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

      10/19/22 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on IsoPlexis with a new price target

      Morgan Stanley reiterated coverage of IsoPlexis with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

      2/15/22 10:15:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVB Leerink reiterated coverage on IsoPlexis with a new price target

      SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

      1/27/22 4:33:30 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI Group initiated coverage on IsoPlexis with a new price target

      Evercore ISI Group initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $24.00

      11/19/21 7:09:33 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by IsoPlexis Corporation (Amendment)

      SC 13D/A - IsoPlexis Corp (0001615055) (Subject)

      6/15/23 4:15:39 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 4:33:58 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 2:40:05 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    SEC Filings

    See more
    • SEC Form 15-12G filed by IsoPlexis Corporation

      15-12G - IsoPlexis Corp (0001615055) (Filer)

      3/31/23 8:32:18 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits

      8-K - IsoPlexis Corp (0001615055) (Filer)

      3/22/23 8:13:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by IsoPlexis Corporation

      S-8 POS - IsoPlexis Corp (0001615055) (Filer)

      3/21/23 5:20:43 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Leadership Updates

    Live Leadership Updates

    See more
    • IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

      BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

      11/30/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Khakhar Rajesh T.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 5:04:56 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Myers Jason W.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:53:55 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Ho Gregory P.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:52:06 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care